SCOLR Pharma, Inc. (DDD 0.36, -0.06, -14.07%) has announced that it has signed an agreement with The Emerson Group to provide sales support for the Company's new line of extended-release nutritional and over-the-counter drug products.
The Emerson Group (www.emersongroup.com), headquartered in Wayne, Pa., is a consumer products equity organization that provides strategic consulting and sales execution services to companies in the United States market.
The Emerson Group will provide strategy consulting, sales, distribution, logistics and account management services in support of SCOLR's new line of extended-release nutritional and over-the-counter drug products, which utilize the Company's proprietary controlled delivery technology(R).
Stephen J. Turner, SCOLR Pharma's President and CEO, said, "The Emerson Group has experience with virtually every over-the-counter category and a well established record of success in building overall sales and visibility with retailers. We look forward to the addition of this capability as we grow our consumer products business."
About SCOLR Pharma:
Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.